PRIME MEDICINE INC (PRME)
Health Care · Gene Editing / Gene Therapy · NASDAQ
Prime Editing-focused gene therapy company advancing a novel gene editing platform to treat genetic diseases and untreated medical conditions.
What PRIME MEDICINE INC does
Prime Medicine is a clinical-stage biotechnology company focused on developing therapeutic products based on its Prime Editing technology, a gene editing platform designed to address unmet medical needs. The company is advancing multiple product candidates across various therapeutic areas through preclinical studies and clinical trials. Prime Medicine generates limited revenue through collaboration agreements while investing substantially in research and development to advance its pipeline of prime editing-based therapeutics.
Themes: ["Gene editing / prime editing"]
Fundamentals
- Price$4.23 as of 2026-07-09 close
- Market cap$764M as of 2026-07-10
- 1-year return+12.7% as of 2026-07-09 close
- Net margin-4917.6% as of 2026-07-10
- ROE-188.8% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)+4.9% as of 2026-07-10
- Beta2.17 as of 2026-07-10
Key risks (from latest filing)
["Substantial R&D losses ($34M+ in Q1 2026) with limited revenue ($856K in Q1 2026 collaboration revenue) create significant funding requirements and cash burn; company is unprofitable with negative net margin of -4917%"]
Competitors & peers
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.